Wallez Solène, Kousignian Isabelle, Hecker Irwin, Rezag Bara Selma Faten, Andersen Astrid Juhl, Melchior Maria, Cadwallader Jean-Sébastien, Mary-Krause Murielle
Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, IPLESP, Equipe de Recherche en Epidémiologie Sociale, ERES, Paris, 75012, France.
Université Paris Cité, Unité de Recherche « Biostatistique, Traitement Et Modélisation Des Données Biologiques » BioSTM - UR 7537, 75006, Paris, France.
J Cannabis Res. 2024 Apr 10;6(1):19. doi: 10.1186/s42238-024-00230-2.
Medical cannabis, legalized in many countries, remains illegal in France. Despite an experiment in the medical use of cannabis that began in March 2021 in France, little is known about the factors associated with the use of cannabis for self-medication among adults.
Data came from the French TEMPO cohort and were collected between December 2020 and May 2021. Overall, 345 participants aged 27-47 were included. Cannabis for self-medication was defined using the following questions: 'Why do you use cannabis?' and 'In what form do you use cannabis?'. The penalized regression method "Elastic net" was used to determine factors associated with the use of cannabis for self-medication, with the hypothesis that it is mainly used for pain in individuals who have already used cannabis.
More than half of the participants reported having ever used cannabis (58%). Only 10% used it for self-declared medical reasons (n = 36). All self-medication cannabis users, except one, were also using cannabis for recreational purposes. The main factors associated with cannabis use for self-medication vs. other reasons included cannabis use trajectories, the presence of musculoskeletal disorders, tobacco smoking, and parental divorce.
Engaging in cannabis use during adolescence or early adulthood may increase the likelihood of resorting to self-medication in adulthood. Due to the propensity of individuals with cannabis use during adolescence to resort to uncontrolled products for self-medication, this population should be more systematically targeted and screened for symptoms and comorbidities that may be associated with cannabis use.
医用大麻在许多国家已合法化，但在法国仍属非法。尽管法国于2021年3月开始了一项大麻医疗用途的试验，但对于成年人中使用大麻进行自我治疗的相关因素知之甚少。
数据来自法国TEMPO队列，于2020年12月至2021年5月收集。总体而言，纳入了345名年龄在27至47岁之间的参与者。使用以下问题来定义用于自我治疗的大麻：“你为什么使用大麻？”以及“你以什么形式使用大麻？”。采用惩罚回归方法“弹性网络”来确定与使用大麻进行自我治疗相关的因素，假设其主要用于已经使用过大麻的个体的疼痛治疗。
超过一半的参与者报告曾使用过大麻（58%）。只有10%的人出于自我宣称的医疗原因使用大麻（n = 36）。除一人外，所有自我治疗用大麻使用者也将大麻用于娱乐目的。与因自我治疗而使用大麻而非其他原因相关的主要因素包括大麻使用轨迹、肌肉骨骼疾病的存在、吸烟和父母离异。
在青春期或成年早期使用大麻可能会增加成年后进行自我治疗的可能性。由于青春期使用大麻的个体倾向于使用不受控制的产品进行自我治疗，应对该人群进行更系统的针对性筛查，以查找可能与大麻使用相关的症状和合并症。
